vs
G III APPAREL GROUP LTD（GIII）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
G III APPAREL GROUP LTD的季度营收约是Revvity的1.3倍（$988.6M vs $772.1M），Revvity净利率更高（12.7% vs 8.2%，领先4.6%），Revvity同比增速更快（5.9% vs -9.0%），Revvity自由现金流更多（$161.8M vs $-106.4M），过去两年G III APPAREL GROUP LTD的营收复合增速更高（13.7% vs 9.0%）
GIII服装集团是一家国际时尚企业，设计、生产及销售服装、鞋履、配饰等产品，拥有多个知名自有及授权品牌，覆盖休闲、运动、轻奢等多个品类，主要销往北美、欧洲等全球市场，合作客户包括百货商场、专业零售商及电商平台。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GIII vs RVTY — 直观对比
营收规模更大
GIII
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出14.9%
-9.0%
净利率更高
RVTY
高出4.6%
8.2%
自由现金流更多
RVTY
多$268.2M
$-106.4M
两年增速更快
GIII
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $988.6M | $772.1M |
| 净利润 | $80.6M | $98.4M |
| 毛利率 | 38.6% | — |
| 营业利润率 | 11.4% | 14.5% |
| 净利率 | 8.2% | 12.7% |
| 营收同比 | -9.0% | 5.9% |
| 净利润同比 | -29.8% | 3.9% |
| 每股收益（稀释后） | $1.84 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GIIIRVTY
| Q4 25 | $988.6M | $772.1M | ||
| Q3 25 | $613.3M | $698.9M | ||
| Q2 25 | $583.6M | $720.3M | ||
| Q1 25 | $839.5M | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $644.8M | $684.0M | ||
| Q2 24 | $609.7M | $691.7M | ||
| Q1 24 | $764.8M | $649.9M |
净利润GIIIRVTY
| Q4 25 | $80.6M | $98.4M | ||
| Q3 25 | $10.9M | $46.7M | ||
| Q2 25 | $7.8M | $53.9M | ||
| Q1 25 | $48.8M | $42.2M | ||
| Q4 24 | $114.8M | $94.6M | ||
| Q3 24 | $24.2M | $94.4M | ||
| Q2 24 | $5.8M | $55.4M | ||
| Q1 24 | $28.9M | $26.0M |
毛利率GIIIRVTY
| Q4 25 | 38.6% | — | ||
| Q3 25 | 40.8% | 53.6% | ||
| Q2 25 | 42.2% | 54.5% | ||
| Q1 25 | 39.5% | 56.5% | ||
| Q4 24 | 39.8% | — | ||
| Q3 24 | 42.8% | 56.3% | ||
| Q2 24 | 42.5% | 55.7% | ||
| Q1 24 | 36.9% | 54.6% |
营业利润率GIIIRVTY
| Q4 25 | 11.4% | 14.5% | ||
| Q3 25 | 2.7% | 11.7% | ||
| Q2 25 | 1.5% | 12.6% | ||
| Q1 25 | 8.5% | 10.9% | ||
| Q4 24 | 15.3% | 16.3% | ||
| Q3 24 | 6.4% | 14.3% | ||
| Q2 24 | 2.2% | 12.4% | ||
| Q1 24 | 6.1% | 6.8% |
净利率GIIIRVTY
| Q4 25 | 8.2% | 12.7% | ||
| Q3 25 | 1.8% | 6.7% | ||
| Q2 25 | 1.3% | 7.5% | ||
| Q1 25 | 5.8% | 6.4% | ||
| Q4 24 | 10.6% | 13.0% | ||
| Q3 24 | 3.8% | 13.8% | ||
| Q2 24 | 1.0% | 8.0% | ||
| Q1 24 | 3.8% | 4.0% |
每股收益（稀释后）GIIIRVTY
| Q4 25 | $1.84 | $0.86 | ||
| Q3 25 | $0.25 | $0.40 | ||
| Q2 25 | $0.17 | $0.46 | ||
| Q1 25 | $1.00 | $0.35 | ||
| Q4 24 | $2.55 | $0.77 | ||
| Q3 24 | $0.53 | $0.77 | ||
| Q2 24 | $0.12 | $0.45 | ||
| Q1 24 | $0.59 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.1M | $919.9M |
| 总债务越低越好 | $6.5M | — |
| 股东权益账面价值 | $1.8B | $7.3B |
| 总资产 | $2.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资GIIIRVTY
| Q4 25 | $184.1M | $919.9M | ||
| Q3 25 | $301.8M | $931.4M | ||
| Q2 25 | $257.8M | $991.8M | ||
| Q1 25 | $181.4M | $1.1B | ||
| Q4 24 | $104.7M | $1.2B | ||
| Q3 24 | $414.8M | $1.2B | ||
| Q2 24 | $508.4M | $2.0B | ||
| Q1 24 | $507.8M | $1.7B |
总债务GIIIRVTY
| Q4 25 | $6.5M | — | ||
| Q3 25 | $6.9M | — | ||
| Q2 25 | $6.8M | — | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | $213.9M | — | ||
| Q3 24 | $402.5M | — | ||
| Q2 24 | $402.7M | — | ||
| Q1 24 | $402.8M | — |
股东权益GIIIRVTY
| Q4 25 | $1.8B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.5B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产GIIIRVTY
| Q4 25 | $2.8B | $12.2B | ||
| Q3 25 | $2.7B | $12.1B | ||
| Q2 25 | $2.4B | $12.4B | ||
| Q1 25 | $2.5B | $12.4B | ||
| Q4 24 | $2.8B | $12.4B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
负债/权益比GIIIRVTY
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.27× | — | ||
| Q2 24 | 0.26× | — | ||
| Q1 24 | 0.26× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-97.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-106.4M | $161.8M |
| 自由现金流率自由现金流/营收 | -10.8% | 21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 2.6% |
| 现金转化率经营现金流/净利润 | -1.21× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $367.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GIIIRVTY
| Q4 25 | $-97.3M | $182.0M | ||
| Q3 25 | $75.1M | $138.5M | ||
| Q2 25 | $93.8M | $134.3M | ||
| Q1 25 | $333.4M | $128.2M | ||
| Q4 24 | $-111.8M | $174.2M | ||
| Q3 24 | $49.3M | $147.9M | ||
| Q2 24 | $45.5M | $158.6M | ||
| Q1 24 | $361.3M | $147.6M |
自由现金流GIIIRVTY
| Q4 25 | $-106.4M | $161.8M | ||
| Q3 25 | $64.7M | $120.0M | ||
| Q2 25 | $85.7M | $115.5M | ||
| Q1 25 | $323.7M | $112.2M | ||
| Q4 24 | $-120.3M | $149.8M | ||
| Q3 24 | $38.8M | $125.6M | ||
| Q2 24 | $32.8M | $136.6M | ||
| Q1 24 | $352.3M | $129.7M |
自由现金流率GIIIRVTY
| Q4 25 | -10.8% | 21.0% | ||
| Q3 25 | 10.6% | 17.2% | ||
| Q2 25 | 14.7% | 16.0% | ||
| Q1 25 | 38.6% | 16.9% | ||
| Q4 24 | -11.1% | 20.5% | ||
| Q3 24 | 6.0% | 18.4% | ||
| Q2 24 | 5.4% | 19.7% | ||
| Q1 24 | 46.1% | 20.0% |
资本支出强度GIIIRVTY
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 0.8% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% | ||
| Q1 24 | 1.2% | 2.7% |
现金转化率GIIIRVTY
| Q4 25 | -1.21× | 1.85× | ||
| Q3 25 | 6.86× | 2.97× | ||
| Q2 25 | 12.09× | 2.49× | ||
| Q1 25 | 6.83× | 3.03× | ||
| Q4 24 | -0.97× | 1.84× | ||
| Q3 24 | 2.04× | 1.57× | ||
| Q2 24 | 7.84× | 2.87× | ||
| Q1 24 | 12.52× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GIII
| Proprietary Brands | $498.1M | 50% |
| Licensed Brands | $479.2M | 48% |
| Retail Segment | $45.7M | 5% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
